Epsilogen Announces Completion of Oversubscribed £30.75 Million ($41.20 Million) Series B Financing
Retrieved on:
Wednesday, March 2, 2022
Research, Finance, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Oncology, Therapy, Concept, Research, Parasitism, Immunoglobulin E, Immunoglobulin G, USD, Business, Growth, Series, Fund, Consultant, Cancer, Patient capital, Disease, ALSA, Public sector banks in India, UNPRI, Half-life, FR, Vaccine, Financial services, Management, Pharmaceutical industry, Epsilogen Ltd, Novartis Venture Fund, 3B FUTURE Health Fund II, British Patient Capital, Schroders Capital, Epidarex Capital, ALSA Ventures, EPSILOGEN LTD, NOVARTIS VENTURE FUND, 3B FUTURE HEALTH FUND II, BRITISH PATIENT CAPITAL, SCHRODERS CAPITAL, EPIDAREX CAPITAL, ALSA VENTURES
Epsilogen Ltd, a global leader in the development of novel immunoglobulin E (IgE) antibodies to treat cancer, announced it has secured 30.75 million ($41.20 million) in an oversubscribed Series B financing round.
Key Points:
- Epsilogen Ltd, a global leader in the development of novel immunoglobulin E (IgE) antibodies to treat cancer, announced it has secured 30.75 million ($41.20 million) in an oversubscribed Series B financing round.
- The new syndicate joins founding Series A investor Epidarex Capital and Series A investor ALSA Ventures both of whom also committed further capital in this Series B fundraising round.
- MOv18 IgE targets the folate receptor alpha (FR alpha) antigen and is the worlds first IgE antibody to enter the clinic.
- Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer.